Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

MLA

Matsubara, Nobuaki, et al. “Phase 1 Study of Darolutamide (ODM-201): A New-Generation Androgen Receptor Antagonist, in Japanese Patients with Metastatic Castration-Resistant Prostate Cancer.” Cancer Chemotherapy & Pharmacology, vol. 80, no. 6, Dec. 2017, pp. 1063–72. EBSCOhost, https://doi.org/10.1007/s00280-017-3417-3.

APA

Matsubara, N., Mukai, H., Hosono, A., Onomura, M., Sasaki, M., Yajima, Y., Hashizume, K., Yasuda, M., Uemura, M., & Zurth, C. (2017). Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy & Pharmacology, 80(6), 1063–1072. https://doi.org/10.1007/s00280-017-3417-3

Chicago

Matsubara, Nobuaki, Hirofumi Mukai, Ako Hosono, Mai Onomura, Masaoki Sasaki, Yoko Yajima, Kensei Hashizume, Masanobu Yasuda, Miho Uemura, and Christian Zurth. 2017. “Phase 1 Study of Darolutamide (ODM-201): A New-Generation Androgen Receptor Antagonist, in Japanese Patients with Metastatic Castration-Resistant Prostate Cancer.” Cancer Chemotherapy & Pharmacology 80 (6): 1063–72. doi:10.1007/s00280-017-3417-3.